<DOC>
	<DOCNO>NCT00426361</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish central cause cervical cancer . Vaccination pre-teens adolescent , ideally sexual debut thus exposure oncogenic HPV , rational strategy prevention cervical cancer , HPV vaccination could complement exist pre-adolescent/adolescents platform . Therefore , Phase IIIb study design evaluate safety immunogenicity co-administering Boostrix polio ( dTpa-IPV ) GSK Biologicals ' ( 580299 ) HPV-16/18 L1 AS04 vaccine ( Cervarix TM ) compare administration either vaccine alone . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Evaluation Safety Immunogenicity Co-administering Human Papillomavirus ( HPV ) Vaccine With Other Vaccines Healthy Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/legally acceptable representative , , comply requirement protocol enrol study . A female , include , 10 18 year age time first vaccination . Written inform consent/assent obtain subject prior enrolment . For subject legal age consent , write informed consent must obtain subject . For subject legal age consent , write informed consent obtain subject 's parent/LAR , write informed assent must obtain subject . Healthy subject , establish medical history historydirected physical examination , enter study . Previously complete routine childhood vaccination accord recommended vaccination schedule time . Subjects must negative urine pregnancy test . Subject must nonchildbearing potential , childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series . Subjects reach menarche study , therefore become childbearing potential , must agree follow precaution . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period ( Month 12/13 ) . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day dose vaccine ( ) . Administration routine vaccine 8 day first dose study vaccine allow . Enrolment defer subject outside specify window . A woman plan become pregnant , likely become pregnant planning discontinue contraceptive precaution study period two month last vaccine dose . Pregnant breastfeed woman . Previous vaccination HPV plan administration HPV vaccine foreseen study protocol study period . Previous administration component investigational vaccine Administration diphtheria , tetanus , pertussis ( DTP ) vaccine , diphtheriatetanus ( Td ) booster dTpa vaccine within previous five year . Administration preschool booster Oral Polio Vaccine ( OPV ) Inactivated Polio Virus ( IPV ) vaccine ( 4 5th dose ) within previous five year . Hypersensitivity latex . Known acute chronic , clinically significant neurologic , hepatic renal functional abnormality thrombocytopenia , determine previous physical examination laboratory test . Cancer autoimmune disease treatment . History allergic disease reaction likely exacerbate component vaccine . History encephalopathy within seven day administration previous dose pertussis vaccine attributable another identifiable cause . Temperature &gt; =40Â°C within 48 hour receipt prior dose DTP vaccine ( DTPw and/or DTPa ) , due another identifiable cause . Collapse shocklike state within 48 hour receipt prior dose DTP vaccine ( DTPw and/or DTPa ) . Seizures without fever within three day prior dose DTP vaccine ( Diphtheria , Tetanus , whole cell Pertussis vaccine DTPw and/or Diphtheria , Tetanus , acellular Pertussis vaccine DTPa ) . Persistent , inconsolable cry last &gt; =3 hour , occur within 48 hour prior dose DTP vaccine ( DTPw and/or DTPa ) . Severe Arthustype hypersensitivity reaction follow prior dose tetanus toxoid within previous 10 year . Known exposure diphtheria household exposure pertussis within 30 day ( i.e. , Day 029 ) vaccination Diphtheria , Tetanus , acellular Pertussis inactivate polio virus vaccine ( dTpaIPV ) . Diphtheria and/or tetanus and/or pertussis and/or polio diagnose within 30 day ( i.e. , Day 029 ) vaccination dTpaIPV . Presence contraindication vaccination accord product leaflet commercially available dTpaIPV vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Acute disease time enrolment . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Enrolment postpone subject outside specify window .</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Human Papillomavirus</keyword>
</DOC>